Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer

Jiheum Paek; Maria Lee; Eun Ji Nam; Sang Wun Kim; Young Tae Kim

doi:10.1007/s00404-015-3864-1

Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer

Arch Gynecol Obstet. 2016 Mar;293(3):645-50. doi: 10.1007/s00404-015-3864-1. Epub 2015 Aug 25.

Authors

Jiheum Paek^{1

2}, Maria Lee³, Eun Ji Nam⁴, Sang Wun Kim⁴, Young Tae Kim⁵

Affiliations

¹ Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Republic of Korea.
² Department of Obstetrics and Gynecology, Yonsei University Graduate School, Seoul, Republic of Korea.
³ Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
⁴ Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
⁵ Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea. ytkchoi@yuhs.ac.

PMID: 26305032
DOI: 10.1007/s00404-015-3864-1

Abstract

Purpose: The aim of this study was to confirm the expression of high mobility group box 1 (HMGB1) in patients with epithelial ovarian cancer (EOC) and to evaluate the prognostic significance of HMGB1.

Methods: A total of 74 patients with EOC comprised our cohort. Retrospectively collected tissue microarray from EOC patients treated with debulking surgery followed by taxane and platinum chemotherapy were analyzed for evaluation of the prognostic significance of HMGB1. Expression of HMGB1 was assessed by immunohistochemistry.

Results: The positive staining was detected in 80% of EOC patients and the rate of high HMGB1 expression was 42%. In advanced stage, patients with high HMGB1 expression showed a poorer prognosis than low HMGB1 expression group [median progression-free survival (PFS), 10.8 vs. 21.7 months, P = 0.005]. High HMGB1 expression was an independent predictor for PFS (P = 0.024).

Conclusions: HMGB1 expression is expected as a promising biomarker for EOC and further studies are needed to assess potential roles in EOC.

Keywords: Epithelial ovarian cancer; HMGB1; Prognosis; Progression-free survival.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antineoplastic Agents / therapeutic use
Biomarkers, Tumor / analysis
Biomarkers, Tumor / metabolism*
Bridged-Ring Compounds / therapeutic use
Carcinoma, Ovarian Epithelial
Cytoreduction Surgical Procedures
Disease-Free Survival
Female
Gene Expression Regulation, Neoplastic*
HMGB1 Protein / analysis
HMGB1 Protein / metabolism*
Humans
Immunohistochemistry
Middle Aged
Neoplasm Recurrence, Local / metabolism
Neoplasm Staging
Neoplasms, Glandular and Epithelial / metabolism*
Neoplasms, Glandular and Epithelial / mortality
Neoplasms, Glandular and Epithelial / pathology*
Neoplasms, Glandular and Epithelial / therapy
Ovarian Neoplasms / metabolism*
Ovarian Neoplasms / mortality
Ovarian Neoplasms / pathology*
Ovarian Neoplasms / therapy
Prognosis
Receptor for Advanced Glycation End Products / analysis
Receptor for Advanced Glycation End Products / metabolism*
Retrospective Studies
Survival Rate
Taxoids / therapeutic use
Tissue Array Analysis
Treatment Outcome

Substances

Antineoplastic Agents
Biomarkers, Tumor
Bridged-Ring Compounds
HMGB1 Protein
Receptor for Advanced Glycation End Products
Taxoids
taxane